Cost and workload implications of routine [18F]FDG PET/CT screening in breast cancer patients scheduled for preoperative systemic therapy: a real-world data analysis

In the context of rising healthcare costs, increasing cancer incidence, and growing pressure on radiology services and workforce shortages, critical evaluation of [ 18 F]FDG PET/CT use in breast cancer patients is warranted. This study assessed the cost and workload implications of routine [ 18 F]FDG PET/CT in patients scheduled for preoperative systemic therapy (PST). We performed a retrospective real-world data analysis of patients scheduled for PST between 2011 and 2020 at our institute, all of whom underwent [ 18 F]FDG PET/CT prior to treatment. Breast cancer-related and non-breast cancer findings, subsequent diagnostic procedures, and final diagnoses were recorded and classified by clinical relevance. Scenario analyses evaluated the impact of de-escalating [ 18 F]FDG PET/CT use in selected patient groups. Among 1,330 patients, [ 18 F]FDG PET/CT resulted in 522 additional investigations and upstaging in 20% of patients. Total costs were €1,94 million and total workload 2,506 h, of which 24% was attributable to upstaged patients. Mean cost and workload per patient increased with clinical stage, while upstaging rates ranged from 6% (stage I) to 35% (stage III). Incidental, non-breast cancer findings were identified in 13% of patients, accounting for 7% of total diagnostic costs and workload. Omitting [ 18 F]FDG PET/CT in stages I-IIA could reduce estimated annual costs and workload by around 60%. Routine [ 18 F]FDG PET/CT in breast cancer patients undergoing PST is associated with substantial costs and workload, largely driven by findings without impact on treatment planning. In stage I-IIA disease, the limited clinical benefit may not justify routine use, supporting a more selective, value-based approach to pre-PST staging.

Authors

Institutions

Publication Details

Journal
BMC Health Services Research
Published
2026-11-19
DOI
https://doi.org/10.1186/s12913-026-15888-y
Primary Topic
Medical Imaging Techniques and Applications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cost and workload implications of routine [18F]FDG PET/CT screening in breast cancer patients scheduled for preoperative systemic therapy: a real-world data analysis

Astrid N. Scholten, A. Marjolein Schrijver, Jetske L B Gunster, Marcel P. M. Stokkel et al.
BMC Health Services Research
Medical Imaging Techniques and Applications
article

Cost and workload implications of routine [18F]FDG PET/CT screening in breast cancer patients scheduled for preoperative systemic therapy: a real-world data analysis

Astrid N. Scholten, A. Marjolein Schrijver, Jetske L B Gunster, Marcel P. M. Stokkel, Josefien P. van Olmen, Astrid Kramer, Frederieke H van Duijnhoven, Valesca P. Retèl, Corrie Marijnen
article en

Abstract

In the context of rising healthcare costs, increasing cancer incidence, and growing pressure on radiology services and workforce shortages, critical evaluation of [ 18 F]FDG PET/CT use in breast cancer patients is warranted. This study assessed the cost and workload implications of routine [ 18 F]FDG PET/CT in patients scheduled for preoperative systemic therapy (PST). We performed a retrospective real-world data analysis of patients scheduled for PST between 2011 and 2020 at our institute, all of whom underwent [ 18 F]FDG PET/CT prior to treatment. Breast cancer-related and non-breast cancer findings, subsequent diagnostic procedures, and final diagnoses were recorded and classified by clinical relevance. Scenario analyses evaluated the impact of de-escalating [ 18 F]FDG PET/CT use in selected patient groups. Among 1,330 patients, [ 18 F]FDG PET/CT resulted in 522 additional investigations and upstaging in 20% of patients. Total costs were €1,94 million and total workload 2,506 h, of which 24% was attributable to upstaged patients. Mean cost and workload per patient increased with clinical stage, while upstaging rates ranged from 6% (stage I) to 35% (stage III). Incidental, non-breast cancer findings were identified in 13% of patients, accounting for 7% of total diagnostic costs and workload. Omitting [ 18 F]FDG PET/CT in stages I-IIA could reduce estimated annual costs and workload by around 60%. Routine [ 18 F]FDG PET/CT in breast cancer patients undergoing PST is associated with substantial costs and workload, largely driven by findings without impact on treatment planning. In stage I-IIA disease, the limited clinical benefit may not justify routine use, supporting a more selective, value-based approach to pre-PST staging.

BMC Health Services Research
Leiden University Medical Center (NL), The Netherlands Cancer Institute (NL), Erasmus University Rotterdam (NL)
Medical Imaging Techniques and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon